About the Company
Scopus BioPharma Inc. is a biopharmaceutical company developing transformational therapeutics capitalizing on groundbreaking scientific and medical discoveries from leading research and academic institutions. The company’s lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. This drug candidate is highly distinctive, encompassing both gene therapy and immunotherapy by synthetically linking siRNA to an oligonucleotide TLR9 agonist, creating the potential for targeted gene silencing with simultaneous TLR stimulation and immune activation in the tumor microenvironment. The company is also developing additional new chemical entities to treat other serious diseases with significant unmet medical needs, including systemic sclerosis.
Exchange
NASDAQ
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $SCPS News
Scopus BioPharma Inc SCPS
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Cue Biopharma Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
SBFM Sunshine Biopharma, Inc.
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals. The company is ...
GT Biopharma Inc GTBP
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
David S. Battleman's Net Worth
Who is David S. Battleman? David S. Battleman does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which ...
Q4 2023 Cue Biopharma Inc Earnings Call
Stephen Willey; Analyst; Stifel Financial Corp. Reni Benjamin; Analyst; JMP Securities LLC Operator Greetings, and welcome to the Cue Biopharma Investor Update Call. (Operator Instructions ...
Theravance Biopharma Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Immix Biopharma Suspends Stock Offering Pending New Prospectus
Immix Biopharma, Inc. (IMMX) has released an update. Immix Biopharma, Inc. has halted the offering of its common stock shares ...
Vor Biopharma, Inc.
Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to ...
Scopus BioPharma Inc. (SCPS)
*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
TBPH Theravance Biopharma, Inc.
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized ...
Loading the latest forecasts...